The Alliance for Safe Biologic Medicines submitted comments to the Federal Trade Commission in regards to the “Follow-On Biosimilars Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition” hearing held in February. Read comments here.
![Background Image](https://safebiologics.org/wp-content/themes/safebiologics/assets/images/default-page-bg.jpg)